PeerVoice Oncology & Haematology Video

Apr 02 2025 187 ep. 23 mins 842
PeerVoice Oncology & Haematology Video Podcast artwork

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

  Science  Health & Fitness  Education
RSS feed Share
Copy RSS


Subscribe on Podcast Addict


Alon Altman, MD, FRCSC, CCPE - It Takes Two: Integrating Immunotherapy in Combination With Chemotherapy Into Recurrent or Primary Advanced Endometrial Cancer Care

Apr 02 2025 9 mins  
Visit https://www.peervoice.com/YCX860 to view the entire programme with slides. After completing “Alon Altman, MD, FRCSC, CCPE - It Takes Two: Integrating Immunotherapy in Combination With Chemotherapy Into Recurrent or Primary Advanced Endometrial Cancer Care”, participants will be able to: Discuss current unmet needs in the frontline management of advanced endometrial cancer

Enrico Lopriore, MD, PhD - Are You Managing Pregnant Individuals? Then You Need to Know About Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT)

Mar 26 2025 25 mins  
Visit https://www.peervoice.com/YZR860 to view the entire programme with slides. After completing “Enrico Lopriore, MD, PhD - Are You Managing Pregnant Individuals? Then You Need to Know About Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT)”, participants will be able to: Explain the pathogenesis of fetal-neonatal alloimmune thrombocytopenia (FNAIT); Identify individuals wit

Alessandro M. Vannucchi, MD, PhD - Not All JAKis Are Equal: What Can Trials and Real-World Evidence Tell Us About Optimal Treatment Approaches in Myelofibrosis?

Mar 26 2025 18 mins  
Visit https://www.peervoice.com/CFP860 to view the entire programme with slides. After completing “Alessandro M. Vannucchi, MD, PhD - Not All JAKis Are Equal: What Can Trials and Real-World Evidence Tell Us About Optimal Treatment Approaches in Myelofibrosis?”, participants will be able to: Recall the results of clinical trials and real-world studies evaluating the effects of a

Kim Ma, MD - Addressing Unmet Needs in ER+, HER- Advanced Breast Cancer: The Evolution of Endocrine Therapy

Mar 19 2025 20 mins  
Visit https://www.peervoice.com/HTG860 to view the entire programme with slides. After completing “Kim Ma, MD - Addressing Unmet Needs in ER+, HER- Advanced Breast Cancer: The Evolution of Endocrine Therapy”, participants will be able to: Describe the clinical rationale for oral selective estrogen receptor degraders (SERDs) for patients with ER+, HER2- advanced breast cancer; E

Amrita Krishnan, MD - The Specifics of Bispecific Antibodies for Multiple Myeloma

Mar 19 2025 9 mins  
Visit https://www.peervoice.com/QCE860 to view the entire programme with slides. After completing “Amrita Krishnan, MD - The Specifics of Bispecific Antibodies for Multiple Myeloma”, participants will be able to: Identify patients who may benefit from bispecific antibody therapy based on individual factors (such as disease characteristics or prior lines of treatment); and Imple

Versha Banerji, MD, FRCPC - The Ties That Bind: Exploring the Role of Noncovalent BTK Inhibitors in CLL Treatment

Mar 12 2025 10 mins  
Visit https://www.peervoice.com/WJH860 to view the entire programme with slides. After completing “Versha Banerji, MD, FRCPC - The Ties That Bind: Exploring the Role of Noncovalent BTK Inhibitors in CLL Treatment”, participants will be able to: Explain differences in mechanism of action between covalent BTK inhibitors and noncovalent BTK inhibitors; Discuss the clinical evidenc

Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Decisions

Mar 05 2025 20 mins  
Visit https://www.peervoice.com/JJY860 to view the entire programme with slides. After completing “Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Decisions”, participants will be able to: Recognise the significant symptom- and treatment-related burdens associated with cytopenic myelofibros

Rachel Goodwin, MD, MSc, FRCPC - Improving Care for Advanced Colorectal Cancer With Later-Line Treatments

Jan 13 2025 12 mins  
Visit https://www.peervoice.com/TJF860 to view the entire programme with slides. After completing “Rachel Goodwin, MD, MSc, FRCPC - Improving Care for Advanced Colorectal Cancer With Later-Line Treatments”, participants will be able to: Outline current treatment recommendations for the management of refractory metastatic colorectal cancer (mCRC); Analyze the clinical evidence o

Dirk Arnold, MD, PhD - Still in the Game! Optimising Treatment Sequencing in the Management of Relapsed or Refractory mCRC

Dec 27 2024 42 mins  
Visit https://www.peervoice.com/YJY860 to view the entire programme with slides. After completing “Dirk Arnold, MD, PhD - Still in the Game! Optimising Treatment Sequencing in the Management of Relapsed or Refractory mCRC”, participants will be able to: Summarise the unmet needs in the management of patients with relapsed or refractory (R/R) metastatic colorectal cancer (mCRC);

Linda Lee, MD, FRCPC / Jacob Rullo, MD, PhD, FRCSC - Managing MEK-Inhibitor–Associated Retinopathy in Metastatic Melanoma: An Expert Discussion

Dec 13 2024 9 mins  
Visit https://www.peervoice.com/RBQ860 to view the entire programme with slides. After completing “Linda Lee, MD, FRCPC / Jacob Rullo, MD, PhD, FRCSC - Managing MEK-Inhibitor–Associated Retinopathy in Metastatic Melanoma: An Expert Discussion”, participants will be able to: Describe the incidence and underlying pathophysiology of MEK-inhibitor—associated serous retinopathy